August 22, 2014 6:05 AM ET

Pharmaceuticals

Company Overview of Drais Pharmaceuticals, Inc.

Company Overview

Drais Pharmaceuticals, Inc. is a drug development company that focuses on early and mid-stage clinical development through proof of concept. Its pipeline of products include ASP3291, a cyclic peptide melanocortin receptor 1 agonist that is used for the treatment of ulcerative colitis; ASP7147, a small molecule bombesin-2 receptor antagonist to improve symptoms in patients with diarrhea-predominant irritable bowel syndrome; and ASP7035, a small molecule selective vasopressin 2 receptor agonist for the treatment of nocturia. Drais Pharmaceuticals, Inc. was founded in 2007 and is based in Bridgewater, New Jersey.

520 US Highway 22

Suite 201

Bridgewater, NJ 08807

United States

Founded in 2007

Phone:

908-895-1200

Fax:

908-895-1201

Key Executives for Drais Pharmaceuticals, Inc.

Co-Founder
Senior Director of Finance & Contracts
Vice President of Clinical Research
Vice President of Nonclinical & Translational Development
Vice President of Project Management
Compensation as of Fiscal Year 2014.

Drais Pharmaceuticals, Inc. Key Developments

Drais Pharmaceuticals, Inc. Presents at BioNJ 2014 International BioPartnering Conference, Apr-10-2014

Drais Pharmaceuticals, Inc. Presents at BioNJ 2014 International BioPartnering Conference, Apr-10-2014 . Venue: The Westin Princeton, Forrestal Village, New Jersey, United States. Speakers: Donna L. Tempel, Chief Executive Officer, President and Director.

Drais Pharmaceuticals, Inc. Presents at BioNJ CEO Summit 2013, Oct-04-2013 11:15 AM

Drais Pharmaceuticals, Inc. Presents at BioNJ CEO Summit 2013, Oct-04-2013 11:15 AM. Venue: Bridgewater Marriott, Bridgewater, New Jersey, United States. Speakers: Donna Tempel, Chief Executive Officer, President and Director.

Astellas Pharma, Inc. and Drais Pharmaceuticals, Inc. Partner to Develop Third Astellas Compound Through Tacurion

Astellas Pharma, Inc. and Drais Pharmaceuticals, Inc. announced that they have entered into a third partnership in the past year to develop and commercialize an Astellas compound. Under the terms of the agreement, Astellas will license ASP7035, of which a phase I study has been completed and is a phase IIa-ready, vasopressin V2 receptor selective agonist for the treatment of nocturia, to Tacurion Pharma, Inc., a virtual company that will be operated by the Drais executive team. The partnership is similar to two prior Astellas and Drais agreements, to advance ASP3291 and ASP7147 through Telsar Pharma, Inc. and Seldar Pharma, Inc. respectively -- both also virtual companies. As with Telsar and Seldar, Tacurion will be operated by Drais, which has substantial clinical development experience. Under the terms of the agreement, Tacurion has an exclusive worldwide license to develop and commercialize ASP7035. Tacurion will be responsible for all development, manufacturing and commercialization activities and their associated costs. Astellas is entitled to receive a milestone payment and royalties on future sales of ASP7035. Astellas also has a onetime option (but not an obligation) to acquire Tacurion upon the success of a proof of concept study. The company expects to initiate the phase II proof-of-concept study in the third quarter of 2013.

Similar Private Companies By Industry

Company Name Region
Heart Rhythm Technologies Incorporated United States
Sequoia Pharmaceuticals, Inc. United States
TRF Pharma, Inc. United States
Vaxin Inc. United States
MicroDisc Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Drais Pharmaceuticals, Inc., please visit www.draispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.